We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
Read MoreHide Full Article
Inogen, Inc. (INGN - Free Report) has been gaining from its unique direct-to-customer business model. Solid performance in the first quarter of 2021 and a strong product portfolio also buoy optimism. However, continued pandemic-led adverse results and foreign exchange fluctuations are major downsides.
Over the past year, the Zacks Rank #2 (Buy) stock has gained 102.4% compared with the 24.6% growth of the industry and 41.3% rise of the S&P 500.
The renowned provider of portable oxygen concentrators (POCs) has a market capitalization of $1.53 billion. The company projects 32.6% growth for 2022 and expects to witness continued improvements in its business. Inogen surpassed the Zacks Consensus Estimates in three of the trailing four quarters and missed the same in one, delivering an earnings surprise of 14.29%, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Unique Direct-to-Customer Business Model: We are upbeat about the sequential improvement in Inogen’s direct-to-consumer sales revenues in the first quarter of 2021. This uptick was primarily on the back of higher demand for POCs. Also, higher vaccination rates within Inogen’s patient population, and the relaxation of COVID-19 PHE-related closure orders leading to increased ambulation, additional stimulus payments and improved consumer confidence, drove product sales.
Strong Product Portfolio: We are optimistic about Inogen’s expanding product portfolio. The company provides oxygen concentrator solutions for portable and stationary use. Inogen’s flagship product, Inogen One G4, is a single-solution POC. Other notable products offered by the company include Inogen One G5 in the domestic business-to-business arm and Inogen One G3 POC. Inogen has officially launched the Inogen One G5 on its direct-to-consumer channel as well. Inogen At Home is aptly formulated for patients who need oxygen therapy while asleep.
Inogen has also received confirmation that the Inogen One G5 POC was cleared for reimbursement in France and Germany. Management also confirmed Inogen’s plan of incorporating the Tidal Assist Ventilator (“TAV”) directly into the Inogen One POCs and making the Sidekick TAV product compatible with the Inogen At-Home Stationary Concentrator.
Strong Q1 Results: Inogen’s better-than-expected results in first-quarter 2021 buoy optimism. The company saw growth in revenues within its Rental and domestic business-to-business segments during the period. Significant gross margin expansion is another plus. Sequential growth in total revenues is encouraging. A solid product portfolio also acts as a catalyst.
However, downsides might result from Inogen’s operation in the international market from which it generates a significant portion of its revenues. We expect adverse foreign currency exchange rates to impede revenue growth in the near term, owing to the strengthening of the U.S. dollar against other foreign currencies.
Inogen has been putting up a dismal overall performance over the past few months, primarily due to pandemic-led challenges. In first-quarter 2021, the company witnessed a drop in total revenues as well as softness in segmental revenues. International business-to-business sales also fell significantly, mainly due to the continued pandemic-led impacts, along with intermittent lockdowns in many European countries, and reduced operational capacity of certain European respiratory assessment centers.
Estimate Trend
Inogen has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its loss per share has narrowed from a loss of 78 cents per share to a loss of 43 cents per share.
The Zacks Consensus Estimate for second-quarter 2021 revenues is pegged at $88.2 million, suggesting a 22.9% rise from the year-ago reported number.
Other Key Picks
A few other top-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Add Inogen (INGN) to Your Portfolio
Inogen, Inc. (INGN - Free Report) has been gaining from its unique direct-to-customer business model. Solid performance in the first quarter of 2021 and a strong product portfolio also buoy optimism. However, continued pandemic-led adverse results and foreign exchange fluctuations are major downsides.
Over the past year, the Zacks Rank #2 (Buy) stock has gained 102.4% compared with the 24.6% growth of the industry and 41.3% rise of the S&P 500.
The renowned provider of portable oxygen concentrators (POCs) has a market capitalization of $1.53 billion. The company projects 32.6% growth for 2022 and expects to witness continued improvements in its business. Inogen surpassed the Zacks Consensus Estimates in three of the trailing four quarters and missed the same in one, delivering an earnings surprise of 14.29%, on average.
Let’s delve deeper.
Unique Direct-to-Customer Business Model: We are upbeat about the sequential improvement in Inogen’s direct-to-consumer sales revenues in the first quarter of 2021. This uptick was primarily on the back of higher demand for POCs. Also, higher vaccination rates within Inogen’s patient population, and the relaxation of COVID-19 PHE-related closure orders leading to increased ambulation, additional stimulus payments and improved consumer confidence, drove product sales.
Strong Product Portfolio: We are optimistic about Inogen’s expanding product portfolio. The company provides oxygen concentrator solutions for portable and stationary use. Inogen’s flagship product, Inogen One G4, is a single-solution POC. Other notable products offered by the company include Inogen One G5 in the domestic business-to-business arm and Inogen One G3 POC. Inogen has officially launched the Inogen One G5 on its direct-to-consumer channel as well. Inogen At Home is aptly formulated for patients who need oxygen therapy while asleep.
Inogen has also received confirmation that the Inogen One G5 POC was cleared for reimbursement in France and Germany. Management also confirmed Inogen’s plan of incorporating the Tidal Assist Ventilator (“TAV”) directly into the Inogen One POCs and making the Sidekick TAV product compatible with the Inogen At-Home Stationary Concentrator.
Strong Q1 Results: Inogen’s better-than-expected results in first-quarter 2021 buoy optimism. The company saw growth in revenues within its Rental and domestic business-to-business segments during the period. Significant gross margin expansion is another plus. Sequential growth in total revenues is encouraging. A solid product portfolio also acts as a catalyst.
However, downsides might result from Inogen’s operation in the international market from which it generates a significant portion of its revenues. We expect adverse foreign currency exchange rates to impede revenue growth in the near term, owing to the strengthening of the U.S. dollar against other foreign currencies.
Inogen has been putting up a dismal overall performance over the past few months, primarily due to pandemic-led challenges. In first-quarter 2021, the company witnessed a drop in total revenues as well as softness in segmental revenues. International business-to-business sales also fell significantly, mainly due to the continued pandemic-led impacts, along with intermittent lockdowns in many European countries, and reduced operational capacity of certain European respiratory assessment centers.
Estimate Trend
Inogen has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its loss per share has narrowed from a loss of 78 cents per share to a loss of 43 cents per share.
The Zacks Consensus Estimate for second-quarter 2021 revenues is pegged at $88.2 million, suggesting a 22.9% rise from the year-ago reported number.
Other Key Picks
A few other top-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%. The company presently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>